Lanreotide acetate

Suppliers

Names

[ Name ]:
Lanreotide acetate

[Synonym ]:
(4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxo-2-butanyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)-D-alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (1:1)
9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt)
1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]-19-[[(2R)-2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-, (4R,7S,10S,13R,16S,19R)-, acetate (1:1) (salt)
Somatuline
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt)
9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-carboxamidacetat(salt)
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-19-[(3-naphthalen-2-yl-D-alanyl)amino]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt)
Somatuline LP
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-19-[(3-naphthalen-2-yl-D-alanyl)amino]-6,9,12,15,18-pe
lanreotide acetate
(4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-carboxamidacetat(salt)
(4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,
Somatuline LA
ntaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt)
Somatuline Autogel
1,2-dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]-19-[[(2R)-2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxypheny

Chemical & Physical Properties

[ Molecular Formula ]:
C₅₆H₇₃N₁₁O₁₂S₂

[ Molecular Weight ]:
1156.375

[ Exact Mass ]:
1155.488159

[ Appearance of Characters ]:
white to off-white

[ Storage condition ]:
?20°C

Safety Information

[ Symbol ]:

GHS08

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H361

[ Precautionary Statements ]:
P281

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
63

[ Safety Phrases ]:
36/37

[ RIDADR ]:
NONH for all modes of transport

Articles

[Drug therapy for acromegaly].

Orv. Hetil. 154(39) , 1527-34, (2013)

Prolonged overproduction of growth hormone, like insulin-like growth factor-1 hypersecretion leads to acromegaly in adults. This is associated with several co-morbidities and increased mortality. Desp...

Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases.

Pituitary 16(3) , 354-62, (2013)

Acromegaly is a rare, chronic, and debilitating disease that results from excessive growth hormone production. Clinically, this disease is associated with enlargement of soft tissue, excessive skeleta...

Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.

Ann. Endocrinol. (Paris.) 74(1) , 49-52, (2013)

We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and r...